. 2012 May 28;14(3):R126. doi: 10.1186/ar3856

Table 2.

Clinical and laboratory associations of CD61-positive microthrombi, CD68-positive macrophage infiltration, and C4d deposition

		CD61 microthrombi		CD68⁺infiltration		C4d deposition
		+	-	Glomerular	Extraglomerular	Glomerular	Extraglomerular

SLEDAI		20.5 ± 6.9	20.3 ± 6.6	r = 0.5^a	r = 0.3^a	r = -0.1	r = 0.4^a

aPL	+	69%	33%	1.9 ± 1.9	1 ± 1.3	2.6 ± 2.9	0.9 ± 1.4
	-	31%	67%	2.1 ± 3.1	0.4 ± 0.6	2.9 ± 4.7	1 ± 1.2

anti-dsDNA	+	91%	74%	2.8 ± 3.2^a	0.8 ± 1	2.4 ± 2.9	1.2 ± 1.4^a
	-	9%	26%	0.6 ± 0.7	0.5 ± 0.8	3.8 ± 6	0.5 ± 0.5

Low complement	+	94%	87%	2.6 ± 3.1^a	0.7 ± 1	2.4 ± 2.9	1.1 ± 1.4
	-	6%	13%	0.5 ± 0.5	0.9 ± 0.9	5.4 ± 8	0.8 ± 0.5

24-hour proteinuria (g)		3.2 ± 3.1	3.6 ± 3.6	r = 0.4^a	r = 0.4^a	r = 0.1	r = 0.3^a

Hematuria	+	88%	84%	2.7 ± 3.2^a	0.8 ± 0.9	2.7 ± 3.9	1.1 ± 1.4
	-	12%	16%	0.6 ± 0.7	0.6 ± 1.4	2.9 ± 2.9	0.5 ± 0.6

Leukocyturia	+	76.50%	84%	2.7 ± 3.2^a	0.7 ± 0.9	2.7 ± 3.6	1.1 ± 1.4
	-	23.50%	16%	1.3 ± 1.5	0.7 ± 1.2	2.8 ± 4.5	0.8 ± 1

Cellular casts	+	62%	68%	3.1 ± 3.5^a	0.8 ± 0.8	3.1 ± 4.2	1.1 ± 1.2
	-	38%	32%	1.1 ± 1.3	0.7 ± 1.3	2.1 ± 2.7	0.9 ± 1.6

Creatinine clearance		97.9 ± 50.2	84.3 ± 35.6	r = -0.01	r = -0.2	r = 0.1	r = - 0.1

Response to treatment	+	81%	95%	3.1 ± 3.5	0.8 ± 0.9	2.9 ± 4.2	1.2 ± 1.5
	-	19%	5%	2.2 ± 1.4	1.3 ± 1.7	1.9 ± 1.5	0.9 ± 0.4

Mean time to response		25.1 ± 27.9	8.8 ± 10.8	r = -0.15	r = -0.26	r = -0.17	r = -0.05

LN relapse	+	33%	45%	2.8 ± 3.3	0.6 ± 0.7	1.9 ± 2.9	1.1 ± 1.1
	-	67%	55%	3.4 ± 4.4	0.7 ± 0.8	2.9 ± 3.5	1.4 ± 1.9

Renal failure at 1 year	+	17.40%	15%	3.2 ± 3.6	0.8 ± 0.9	2.9 ± 4.2	1.3 ± 1.6
	-	82.60%	85%	1.9 ± 2.1	1.5 ± 1.6	1.3 ± 1.7	1.2 ± 0.7

Renal failure at last visit	+	20.80%	30%	3.3 ± 3.7	0.9 ± 1	3 ± 4.4	1.3 ± 1.6
	-	79.20%	70%	2.1 ± 1.9	1 ± 1.4	1.5 ± 1.7	1 ± 0.7

^aP < 0.05.